MD vs. RGNX, SAGE, ALXO, RLAY, BLFS, ELVN, CTKB, SPRY, CGC, and PLRX
Should you be buying Pediatrix Medical Group stock or one of its competitors? The main competitors of Pediatrix Medical Group include REGENXBIO (RGNX), Sage Therapeutics (SAGE), ALX Oncology (ALXO), Relay Therapeutics (RLAY), BioLife Solutions (BLFS), Enliven Therapeutics (ELVN), Cytek Biosciences (CTKB), ARS Pharmaceuticals (SPRY), Canopy Growth (CGC), and Pliant Therapeutics (PLRX). These companies are all part of the "medical" sector.
REGENXBIO (NASDAQ:RGNX) and Pediatrix Medical Group (NYSE:MD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
In the previous week, REGENXBIO had 2 more articles in the media than Pediatrix Medical Group. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for Pediatrix Medical Group. REGENXBIO's average media sentiment score of 0.45 beat Pediatrix Medical Group's score of 0.34 indicating that Pediatrix Medical Group is being referred to more favorably in the news media.
Pediatrix Medical Group has a net margin of -3.03% compared to Pediatrix Medical Group's net margin of -291.99%. REGENXBIO's return on equity of 10.35% beat Pediatrix Medical Group's return on equity.
Pediatrix Medical Group has higher revenue and earnings than REGENXBIO. Pediatrix Medical Group is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
REGENXBIO has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Pediatrix Medical Group has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
REGENXBIO presently has a consensus price target of $38.45, suggesting a potential upside of 131.10%. Pediatrix Medical Group has a consensus price target of $9.38, suggesting a potential upside of 2.80%. Given Pediatrix Medical Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe REGENXBIO is more favorable than Pediatrix Medical Group.
Pediatrix Medical Group received 77 more outperform votes than REGENXBIO when rated by MarketBeat users. However, 65.89% of users gave REGENXBIO an outperform vote while only 61.35% of users gave Pediatrix Medical Group an outperform vote.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 97.7% of Pediatrix Medical Group shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by company insiders. Comparatively, 2.0% of Pediatrix Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Pediatrix Medical Group beats REGENXBIO on 10 of the 18 factors compared between the two stocks.
Get Pediatrix Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pediatrix Medical Group Competitors List
Related Companies and Tools
